Abstract：
UNASSIGNED: Therapeutic possibilities for non-small cell lung cancer (NSCLC) have considerably increased during recent decades.
UNASSIGNED: To summarize the prognostic relevance of serum tumor markers (STM) for early and late-stage NSCLC patients treated with classical chemotherapies, novel targeted and immune therapies.
UNASSIGNED: A PubMed database search was conducted for prognostic studies on carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), neuron-specific enolase, squamous-cell carcinoma antigen, progastrin-releasing-peptide, CA125, CA 19-9 and CA 15-3 STMs in NSCLC patients published from 2008 until June 2022.
UNASSIGNED: Out of 1069 studies, 141 were identified as meeting the inclusion criteria. A considerable heterogeneity regarding design, patient number, analytical and statistical methods was observed. High pretherapeutic CYFRA 21-1 levels and insufficient decreases indicated unfavorable prognosis in many studies on NSCLC patients treated with chemo-, targeted and immunotherapies or their combinations in early and advanced stages. Similar results were seen for CEA in chemotherapy, however, high pretherapeutic levels were sometimes favorable in targeted therapies. CA125 is a promising prognostic marker in patients treated with immunotherapies. Combinations of STMs further increased the prognostic value over single markers.
UNASSIGNED: Protein STMs, especially CYFRA 21-1, have prognostic potential in early and advanced stage NSCLC. For future STM investigations, better adherence to comparable study designs, analytical methods, outcome measures and statistical evaluation standards is recommended.
UNASSIGNED: To summarize the prognostic relevance of serum tumor markers (STM) for early and late-stage NSCLC patients treated with classical chemotherapies, novel targeted and immune therapies.
UNASSIGNED: A PubMed database search was conducted for prognostic studies on carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), neuron-specific enolase, squamous-cell carcinoma antigen, progastrin-releasing-peptide, CA125, CA 19-9 and CA 15-3 STMs in NSCLC patients published from 2008 until June 2022.
UNASSIGNED: Out of 1069 studies, 141 were identified as meeting the inclusion criteria. A considerable heterogeneity regarding design, patient number, analytical and statistical methods was observed. High pretherapeutic CYFRA 21-1 levels and insufficient decreases indicated unfavorable prognosis in many studies on NSCLC patients treated with chemo-, targeted and immunotherapies or their combinations in early and advanced stages. Similar results were seen for CEA in chemotherapy, however, high pretherapeutic levels were sometimes favorable in targeted therapies. CA125 is a promising prognostic marker in patients treated with immunotherapies. Combinations of STMs further increased the prognostic value over single markers.
UNASSIGNED: Protein STMs, especially CYFRA 21-1, have prognostic potential in early and advanced stage NSCLC. For future STM investigations, better adherence to comparable study designs, analytical methods, outcome measures and statistical evaluation standards is recommended.
摘要：
近几十年来，非小细胞肺癌（NSCLC）的治疗可能性大大增加。
■总结血清肿瘤标志物（STM）对早期和晚期NSCLC患者进行经典化疗的预后相关性，新型靶向和免疫疗法。
■进行了PubMed数据库搜索，以进行有关癌胚抗原（CEA）的预后研究，细胞角蛋白19片段（CYFRA21-1），神经元特异性烯醇化酶，鳞状细胞癌抗原，前胃泌素释放肽，2008年至2022年6月发表的NSCLC患者的CA125，CA19-9和CA15-3STMs。
■在1069项研究中，141人被确定为符合纳入标准。关于设计的相当大的异质性，患者人数,观察了分析和统计方法。高治疗前CYFRA21-1水平和不足的降低表明在许多对化疗的NSCLC患者的研究中预后不良，早期和晚期的靶向和免疫疗法或其组合。CEA在化疗中也有类似的结果，然而,高治疗前水平有时有利于靶向治疗.CA125是接受免疫疗法治疗的患者的有希望的预后标志物。STM的组合进一步增加了比单一标志物的预后价值。
■蛋白质STMs，尤其是CYFRA21-1，在早期和晚期NSCLC中具有预后潜力。对于未来的STM调查，更好地坚持可比的研究设计，分析方法，建议采用结果衡量标准和统计评价标准.
■总结血清肿瘤标志物（STM）对早期和晚期NSCLC患者进行经典化疗的预后相关性，新型靶向和免疫疗法。
■进行了PubMed数据库搜索，以进行有关癌胚抗原（CEA）的预后研究，细胞角蛋白19片段（CYFRA21-1），神经元特异性烯醇化酶，鳞状细胞癌抗原，前胃泌素释放肽，2008年至2022年6月发表的NSCLC患者的CA125，CA19-9和CA15-3STMs。
■在1069项研究中，141人被确定为符合纳入标准。关于设计的相当大的异质性，患者人数,观察了分析和统计方法。高治疗前CYFRA21-1水平和不足的降低表明在许多对化疗的NSCLC患者的研究中预后不良，早期和晚期的靶向和免疫疗法或其组合。CEA在化疗中也有类似的结果，然而,高治疗前水平有时有利于靶向治疗.CA125是接受免疫疗法治疗的患者的有希望的预后标志物。STM的组合进一步增加了比单一标志物的预后价值。
■蛋白质STMs，尤其是CYFRA21-1，在早期和晚期NSCLC中具有预后潜力。对于未来的STM调查，更好地坚持可比的研究设计，分析方法，建议采用结果衡量标准和统计评价标准.
